(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Electronics
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
 
  Advertising
Aerospace, Defense
Automotive
Banking
Biotechnology
Business Services
Chemicals
Company Reports
Construction
Consumer Goods
Countries
Diagnostics
Energy, Environment
Food & Beverages
Government
Healthcare
IT
Manufacturing
Media
Medical Devices
Pharmaceuticals
Retailing
Sales & Marketing
Sourcing
Telecommunications
Transportation
Travel, Entertainment
 
Home > Chemicals Life Science Intermediates >  Life Science Intermediates Market Consolidation: Who will not survive?

Life Science Intermediates Market Consolidation: Who will not survive?



 

- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive?

This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents:

  • Internally developed and acquired technologies, and related capabilities.
  • Proprietary technologies and patent litigations.
The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages



To order sections of this report, contact Client Services


     
   
Local PDF: $2450.00
Other Formats: Global PDF, DataPack
   
   
 
VPGMarketResearch.com © Copyright 2015. all rights reserved. Web Design by Spida Design  
  Close  X